ijms-logo

Journal Browser

Journal Browser

Special Issue "Type 2 Diabetes and Cardiovascular Disease: Pathophysiological Mechanisms and Effects of SGLT-2i and GLP-1RAs"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editors

Prof. Dr. Elena Succurro
E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
Interests: prediabetes; type 2 diabetes; myocardial insulin resistance; cardiovascular organ damage; sex differences in prediabetes, type 2 diabetes and cardiovascular disease; mechanism of action of SGLT2i; gestational diabetes
Prof. Dr. Angela Sciacqua
E-Mail Website
Guest Editor
1. Associate Professor of Internal Medicine, Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
2. National Abilitation to Full Professor of Internal Medicine, 88100 Catanzaro, Italy
3. Director of Specialization School in Geriatrics, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
4. Director of Geriatric Division – Mater Domini University Hospital-Catanzaro, 88100 Catanzaro, Italy
Interests: cardiovascular and metabolic disease (chronic heart failure; arterial hypertension; insulin resistance; type 2 diabetes mellitus; cardiovascular biomarkers so as uric acid)

Special Issue Information

Dear Colleagues,

Type 2 diabetes (T2DM) is an independent risk factor for ischemic heart disease, stroke, and heart failure, and cardiovascular diseases (CVD) are the main cause of mortality and morbidity in patients with T2DM. It is estimated that the incidence of fatal and nonfatal coronary events in diabetic people is 1.5 to 3-4 times higher than in non-diabetic subjects of the same age. Moreover, increasing evidence suggests that the relative risk for CVD and mortality is higher in women than in men with diabetes.

Alterations in endothelial function and oxidative stress can contribute to the development of atherosclerotic lesion and may represent the mechanistic link between type 2 diabetes and cardiovascular diseases.

The prevention of cardiovascular events is a key goal in the management of patients with T2DM. Recent evidence from cardiovascular outcomes trials (CVOTs) demonstrated the benefits of the new classes of antihyperglycemic drugs—sodium-glucose-cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists—on the cardiovascular outcomes. However, the mechanisms through which treatments with SGLT-2i and GLP-1RAs are associated with an improvement in cardiovascular outcomes are not fully understood.

This Special Issue aims to publish original research and review articles concerning significant findings in the field of type 2 diabetes and CVD, in order to explore more processes that contribute to a better understanding of the pathophysiology of cardiovascular disease in patients with T2DM and to learn about new research on the CV protection mechanisms of SGLT-2i and GLP-1RAs.

Prof. Dr. Elena Succurro
Prof. Dr. Angela Sciacqua
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Type 2 diabetes
  • Cardiovascular disease
  • Sex differences in type 2 diabetes and cardiovascular disease
  • SGLT-2i
  • GLP-1RAs
  • Endothelial dysfunction
  • Oxidative stress
  • Atherosclerosis
  • Cardiovascular risk factors
  • Insulin resistance
  • Cardiovascular organ damage
  • Arterial stiffness
  • Prevention of cardiovascular disease
  • Heart failure

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Int. J. Mol. Sci. 2021, 22(11), 5863; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22115863 - 30 May 2021
Cited by 2 | Viewed by 1375
Abstract
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status induced by insulin resistance are crucial in cardiac function impairment, SGLT2i cardioprotective mechanisms against [...] Read more.
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the elderly. Although, in T2DM, both hyperglycemia and the proinflammatory status induced by insulin resistance are crucial in cardiac function impairment, SGLT2i cardioprotective mechanisms against HF are several. In particular, these beneficial effects seem attributable to the significant reduction of intracellular sodium levels, well-known to exert a cardioprotective role in the prevention of oxidative stress and consequent cardiomyocyte death. From a molecular perspective, patients’ exposure to gliflozins’ treatment mimics nutrient and oxygen deprivation, with consequent autophagy stimulation. This allows to maintain the cellular homeostasis through different degradative pathways. Thus, since their introduction in the clinical practice, the hypotheses on SGLT2i mechanisms of action have changed: from simple glycosuric drugs, with consequent glucose lowering, erythropoiesis enhancing and ketogenesis stimulating, to intracellular sodium-lowering molecules. This provides their consequent cardioprotective effect, which justifies its significant reduction in CV events, especially in populations at higher risk. Finally, the updated clinical evidence of SGLT2i benefits on HF was summarized. Thus, this review aimed to analyze the cardioprotective mechanisms of sodium glucose transporter 2 inhibitors (SGLT2i) in patients with HF, as well as their clinical impact on cardiovascular events. Full article
Show Figures

Figure 1

Back to TopTop